CS Professional · Corporate Restructuring, Valuation and Insolvency · Overview of Business Valuation
Two firms in the same industry earn identical profits. Firm A has a growth rate of 12% per annum with a strong brand; Firm B is growing at 2% in a saturating segment. Other factors being equal, which is the likely valuation outcome under an earnings-based approach?
Firm A is likely valued higher. Valuation reflects expected future earnings, and a higher growth rate with a strong brand supports a higher multiple or higher projected cash flows, even when current profits are identical to those of the slower-growing firm.
- AFirm B is valued higher because it is more mature
- BBoth are valued equally since profits are identical
- CFirm A is valued higher because higher expected growth supports a higher multiple or higher projected cash flowsCorrect
- DFirm A is valued lower because growth requires investment
Explanation
Earnings-based valuation capitalises expected future earnings. Higher growth prospects and brand strength support higher projected cash flows and a higher multiple. Equal current profit does not mean equal value, so equal valuation is wrong.
Did you get it right without looking?
One question tells you little. A timed set on Overview of Business Valuation shows your real accuracy, how long you take and where you lose marks.
More Overview of Business Valuation questions
- Gomti Engineering Ltd is financially distressed and a resolution applicant has submitted a plan. The committee of creditors wants to judge w…
- Anita, a company secretary, is asked why a company's valuation is needed before a scheme of amalgamation. Which is the most direct purpose?
- Two companies, Kaveri Foods Ltd and Narmada Snacks Ltd, plan to amalgamate. The boards need to decide how many shares of the transferee comp…
- Kaveri Pharma Ltd, an unlisted company, is to be valued for a share swap. The valuer finds that a minority stake of 8% is being transferred …
- Sunrise Textiles Ltd plans to acquire a smaller rival. Its board asks a valuer to estimate the rival's worth. Before starting any analysis, …
- Kaveri Pharma Ltd is expected to generate free cash flows of Rs 110 lakh next year, growing at a steady 5% a year forever. The discount rate…